620 related articles for article (PubMed ID: 29544869)
1. Criminal justice continuum for opioid users at risk of overdose.
Brinkley-Rubinstein L; Zaller N; Martino S; Cloud DH; McCauley E; Heise A; Seal D
Addict Behav; 2018 Nov; 86():104-110. PubMed ID: 29544869
[TBL] [Abstract][Full Text] [Related]
2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
3. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
[TBL] [Abstract][Full Text] [Related]
4. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
Bahji A; Carlone D; Altomare J
Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
[TBL] [Abstract][Full Text] [Related]
5. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
[TBL] [Abstract][Full Text] [Related]
6. Extended-release naltrexone opioid treatment at jail reentry (XOR).
McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
[TBL] [Abstract][Full Text] [Related]
7. Criminal Justice Barriers to Treatment of Opioid Use Disorders in the United States: The Need for Public Health Advocacy.
Csete J
Am J Public Health; 2019 Mar; 109(3):419-422. PubMed ID: 30676805
[TBL] [Abstract][Full Text] [Related]
8. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Friedmann PD; Hoskinson R; Gordon M; Schwartz R; Kinlock T; Knight K; Flynn PM; Welsh WN; Stein LA; Sacks S; O'Connell DJ; Knudsen HK; Shafer MS; Hall E; Frisman LK;
Subst Abus; 2012; 33(1):9-18. PubMed ID: 22263709
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Opioid Overdose.
Babu KM; Brent J; Juurlink DN
N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
[No Abstract] [Full Text] [Related]
10. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
[TBL] [Abstract][Full Text] [Related]
11. A scoping review of factors that influence opioid overdose prevention for justice-involved populations.
Grella CE; Ostlie E; Scott CK; Dennis ML; Carnevale J; Watson DP
Subst Abuse Treat Prev Policy; 2021 Feb; 16(1):19. PubMed ID: 33618744
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for opioid addiction in community corrections.
Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
[TBL] [Abstract][Full Text] [Related]
14. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
15. Potential uses of naltrexone in emergency department patients with opioid use disorder.
Bradley ES; Liss D; Carreiro SP; Brush DE; Babu K
Clin Toxicol (Phila); 2019 Sep; 57(9):753-759. PubMed ID: 30831039
[No Abstract] [Full Text] [Related]
16. Medication Treatment of Opioid Use Disorder.
Bell J; Strang J
Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
[TBL] [Abstract][Full Text] [Related]
17. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
Krawczyk N; Picher CE; Feder KA; Saloner B
Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
[TBL] [Abstract][Full Text] [Related]
18. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B
Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008
[TBL] [Abstract][Full Text] [Related]
19. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
20. A scoping review of post opioid-overdose interventions.
Bagley SM; Schoenberger SF; Waye KM; Walley AY
Prev Med; 2019 Nov; 128():105813. PubMed ID: 31437462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
